Fate Therapeutics Joins Biopharma's IPO Runway
By Staff Reports
Thursday, August 15, 2013
Hoping to follow in the footsteps of two other companies focused on stem cells Verastem Inc. and Stemline Therapeutics Inc. that successfully completed their initial public offerings (IPOs) in 2012 and 2013 respectively, San Diego-based Fate Therapeutics Inc. filed its S-1 with the SEC to raise up to $69 million in an IPO.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.